Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Exela Pharma Sciences LLC
FDA Inspection
•Exela Pharma Sciences LLC•March 29, 2019

Exela Pharma Sciences LLC – FDA Inspection, Mar 29, 2019

Record Details

This FDA Inspection record concerns Exela Pharma Sciences LLC, with an inspection on March 29, 2019, issued by the Atlanta District Office, covering human drugs.

Company
Exela Pharma Sciences LLC
Inspection Date
March 29, 2019
Product Type
Human Drugs
Office
Atlanta District Office
People
  • Jason R. Caballero (FDA Associated Person)
  • Samantha J. Bradley (FDA Associated Person)
View Company Profile

ID · 4905f687-c73c-4645-b475-2579c09ea06e

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
1084304
FDA center
Human Drugs
Project area
Generic Drug Evaluation
Outcome
Form 483 issued

FDA Citations

10
  1. 21 CFR 211.100(a)Absence of Written Procedures
  2. 21 CFR 211.160(b)Scientifically sound laboratory controls
  3. 21 CFR 211.182Chronological Order of Equipment Log Entries
  4. 21 CFR 211.188Prepared for each batch, include complete information
  5. 21 CFR 211.25(a)Training , Education , Experience overall
  6. 21 CFR 211.42(b)Adequate space lacking to prevent mix-ups and contamination
  7. 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
  8. 21 CFR 211.42(c)(10)(v)Cleaning System
  9. 21 CFR 211.68(a)Calibration/Inspection/Checking not done
  10. 21 CFR 211.80(a)Procedures To Be in Writing

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Exela Pharma Sciences LLC

13
DateClassificationOfficeProject area
November 15, 2024OAIDrug Quality Assurance
July 18, 2019VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
December 19, 2018NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
September 11, 2018NAICenter for Drug Evaluation and ResearchBioresearch Monitoring
October 27, 2017Not classifiedAtlanta District Office
View all 13 other inspections on the company page
Other documents for Exela Pharma Sciences LLC
  • FDA Inspection 1256957 - 2024-11-15
  • FDA Inspection 1096634 - 2019-07-18
  • FDA Inspection 1081405 - 2018-12-19
  • FDA Inspection 1067755 - 2018-09-11
  • FDA Inspection 1032076 - 2017-10-27

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exela Pharma Sciences LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.